Lexicon Pharmaceuticals, Inc. (LXRX) stock
LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3064% above fair value
$1.53−0.14 (-8.38%)
Close on Nov 20, 2026Market cap $680.78MP/E –Yield –
Lexicon Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Lexicon Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2025 was -$67.85M. For fiscal 2025 it was -$67.85M. The highest annual figure on record is $183.87M in fiscal 2015.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$67.85M | – |
| FY2024 | Dec 31, 2024 | -$179.81M | – |
| FY2023 | Dec 31, 2023 | -$162.37M | – |
| FY2022 | Dec 31, 2022 | -$90.18M | – |
| FY2021 | Dec 31, 2021 | -$88.24M | – |
| FY2020 | Dec 31, 2020 | -$143.06M | -225.8% |
| FY2019 | Dec 31, 2019 | $113.74M | – |
| FY2018 | Dec 31, 2018 | -$148.70M | – |
| FY2017 | Dec 31, 2017 | -$185.62M | – |
| FY2016 | Dec 31, 2016 | -$175.86M | -195.6% |
| FY2015 | Dec 31, 2015 | $183.87M | – |
| FY2014 | Dec 31, 2014 | -$75.70M | – |
| FY2013 | Dec 31, 2013 | -$92.80M | – |
| FY2012 | Dec 31, 2012 | -$94.95M | – |
| FY2011 | Dec 31, 2011 | -$89.14M | – |
| FY2010 | Dec 31, 2010 | -$83.50M | – |
| FY2009 | Dec 31, 2009 | -$89.39M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$17.23M | – |
| Q3 FY2025 | Sep 30, 2025 | -$23.83M | – |
| Q4 FY2024 | Dec 31, 2024 | -$21.97M | – |
| Q3 FY2024 | Sep 30, 2024 | -$53.93M | – |
| Q2 FY2024 | Jun 30, 2024 | -$48.79M | – |
| Q1 FY2024 | Mar 31, 2024 | -$55.13M | – |
| Q4 FY2023 | Dec 31, 2023 | -$50.55M | – |
| Q3 FY2023 | Sep 30, 2023 | -$41.70M | – |
| Q2 FY2023 | Jun 30, 2023 | -$38.26M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.86M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.82M | – |
| Q3 FY2022 | Sep 30, 2022 | -$19.44M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.42M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.50M | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.85M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.36M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.83M | – |
| Q1 FY2021 | Mar 31, 2021 | -$25.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$34.29M | – |
| Q3 FY2020 | Sep 30, 2020 | -$40.41M | -121.2% |
| Q2 FY2020 | Jun 30, 2020 | -$46.30M | – |
| Q1 FY2020 | Mar 31, 2020 | -$22.05M | – |
| Q4 FY2019 | Dec 31, 2019 | -$24.37M | – |
| Q3 FY2019 | Sep 30, 2019 | $190.70M | – |
| Q2 FY2019 | Jun 30, 2019 | -$26.90M | – |
| Q1 FY2019 | Mar 31, 2019 | -$25.69M | – |
| Q4 FY2018 | Dec 31, 2018 | -$27.17M | – |
| Q3 FY2018 | Sep 30, 2018 | -$22.18M | – |
| Q2 FY2018 | Jun 30, 2018 | -$52.54M | – |
| Q1 FY2018 | Mar 31, 2018 | -$46.82M | – |
| Q4 FY2017 | Dec 31, 2017 | -$33.72M | – |
| Q3 FY2017 | Sep 30, 2017 | -$34.02M | – |
| Q2 FY2017 | Jun 30, 2017 | -$32.30M | – |
| Q1 FY2017 | Mar 31, 2017 | -$85.59M | – |
| Q4 FY2016 | Dec 31, 2016 | -$48.94M | – |
| Q3 FY2016 | Sep 30, 2016 | -$35.24M | – |
See a number that looks wrong?